RecruitingNCT06767254

A Machine Learning Approach to Connect Multiple Myeloma Complexity to Early Disease Recurrence

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Enrollment

200 participants

Start Date

Oct 30, 2024

Study Type

OBSERVATIONAL

Conditions

Multiple Myeloma (MM)

Summary

This is a non-interventional, national, multicenter prospective non-profit observational study aiming at improving the accuracy of risk prediction in multiple myeloma (MM) by applying machine-learning tools for data processing to develop model(s) predicting response to therapy and the probability of early relapse for MM patients.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is using machine learning (artificial intelligence) to analyze data from multiple myeloma patients to better understand the early signs of disease progression. This is an observational study — no experimental treatment is given — but the data collected may help improve future detection and treatment of myeloma. **You may be eligible if...** - You are 18 years or older - You have an active diagnosis of multiple myeloma - You are willing to sign informed consent and allow your data to be used for the study **You may NOT be eligible if...** - There are no specific exclusion criteria listed for this study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(4)

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS

Meldola, Forlì-Cesena, Italy

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Bologna, Italy

ARNAS "G. Brotzu" di Cagliari

Cagliari, Italy

Azienda Ospedaliera Universitaria Federico II

Naples, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06767254

Related Trials

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

NCT0697478611 locations

Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution

NCT072143244 locations

Benefits of a 6-month, Individualized, Hybrid, "Real-life" Adapted Physical Activity Program on the Quality of Life of Patients Treated for Multiple Myeloma

NCT075470072 locations

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

NCT0728001316 locations

Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.

NCT0710752929 locations